Item request has been placed!
×
Item request cannot be made.
×
Processing Request
The DRD3 Ser9Gly Polymorphism Predicted Metabolic Change in Drug-Naive Patients With Bipolar II Disorder.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
- Publication Information:
Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
- Subject Terms:
- Abstract:
Patients with bipolar II disorder (BDII) have a higher prevalence rate of metabolic disturbance. Whether BDII itself, in addition to its current standard treatment, is a risk factor for metabolic syndrome warrants additional study. The dopamine receptor D3 (DRD3) gene, one of the candidate genes for BDII, is also involved in the dopaminergic system. We investigated whether it is related to changes in the metabolic indices of patients with BDII given 12 weeks of standard treatment.Patients with a first diagnosis of BDII (n = 117) were recruited. Metabolic profiles (cholesterol, triglycerides, fasting serum glucose, body mass index) were measured at baseline and at 2, 8, and 12 weeks. The genotype of the DRD3 Ser9Gly polymorphism (rs6280) was determined. Multiple linear regressions with generalized estimating equation methods were used.Seventy-six (65.0%) patients completed the 12-week intervention. Significant differences in triglyceride change were associated with the DRD3 Ser9Gly genotype (P = 0.03). Patients with the Ser/Ser genotype had significantly smaller triglyceride increases and a lower risk of developing metabolic syndrome than did those with the Ser/Gly+Gly/Gly genotype. However, the associations between the DRD3 Ser9Gly polymorphism with changes in triglyceride level become nonsignificant after correcting for multiple comparisons.We conclude that the DRD3 Ser9Gly polymorphism is nominally associated with changes in triglycerides and metabolic syndrome after 12 weeks of standard BDII treatment.
Competing Interests: All authors declare that they have no conflicts of interest.
- Comments:
Erratum in: Medicine (Baltimore). 2016 Oct 14;95(41):e651b. (PMID: 31265652)
- References:
Nature. 1990 Sep 13;347(6289):146-51. (PMID: 1975644)
J Affect Disord. 2003 Jan;73(1-2):33-8. (PMID: 12507735)
J Affect Disord. 2010 Nov;126(3):366-87. (PMID: 20541810)
Bipolar Disord. 2008 Feb;10(1 Pt 2):163-78. (PMID: 18199235)
J Psychiatr Res. 2013 Oct;47(10):1343-8. (PMID: 23870798)
Front Neuroendocrinol. 2010 Jan;31(1):104-12. (PMID: 19836414)
Bipolar Disord. 2009 Dec;11(8):787-806. (PMID: 19922550)
PLoS One. 2013;8(1):e54108. (PMID: 23365649)
J Clin Psychiatry. 2002 Mar;63(3):207-13. (PMID: 11926719)
Am J Med Genet. 1998 Mar 28;81(2):192-4. (PMID: 9613861)
PLoS One. 2013 Jun 27;8(6):e66847. (PMID: 23826157)
Pharmacogenomics J. 2010 Jun;10(3):200-18. (PMID: 20029384)
Med Sci Monit. 2002 Jan;8(1):CR1-4. (PMID: 11796958)
Behav Res Methods. 2009 Nov;41(4):1149-60. (PMID: 19897823)
Am J Psychiatry. 2013 Mar;170(3):265-74. (PMID: 23361837)
Clin Neuropharmacol. 1992;15 Suppl 1 Pt A:456A-457A. (PMID: 1354048)
Schizophr Res. 2008 Apr;101(1-3):26-35. (PMID: 18295456)
Alcohol Clin Exp Res. 2004 Mar;28(3):374-84. (PMID: 15084894)
Neuroimage. 2008 Mar 1;40(1):275-9. (PMID: 18096411)
Br J Psychiatry. 1978 Nov;133:429-35. (PMID: 728692)
J Affect Disord. 2013 Dec;151(3):967-72. (PMID: 24021960)
Neuropsychobiology. 2001;44(2):95-8. (PMID: 11490179)
Biometrics. 1988 Dec;44(4):1049-60. (PMID: 3233245)
Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. (PMID: 6080235)
Hum Genet. 1996 Jun;97(6):714-9. (PMID: 8641685)
Eur Neuropsychopharmacol. 2012 Sep;22(9):625-31. (PMID: 22386772)
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. (PMID: 14399272)
Biochem Biophys Res Commun. 1996 Aug 23;225(3):1068-72. (PMID: 8780735)
Brain Res. 1991 Nov 15;564(2):203-19. (PMID: 1839781)
J Affect Disord. 2009 Sep;117(1-2):124-9. (PMID: 19193445)
Biometrics. 2012 Dec;68(4):1046-54. (PMID: 22463099)
Am J Med Genet. 2000 Feb 7;96(1):114-7. (PMID: 10686563)
Endocrinology. 2014 Mar;155(3):829-39. (PMID: 24424036)
Eur Neuropsychopharmacol. 2015 Sep;25(9):1427-36. (PMID: 25482686)
Trends Neurosci. 2007 Aug;30(8):375-81. (PMID: 17604133)
Schizophr Bull. 2013 Mar;39(2):306-18. (PMID: 22207632)
J Clin Psychiatry. 2006 Jun;67(6):904-15. (PMID: 16848650)
Bipolar Disord. 2005 Oct;7(5):424-30. (PMID: 16176435)
Psychiatr Genet. 2000 Mar;10(1):43-9. (PMID: 10909128)
Psychiatr Clin North Am. 1999 Sep;22(3):517-34, vii. (PMID: 10550853)
Br J Psychiatry. 2007 Mar;190:189-91. (PMID: 17329735)
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):275-82. (PMID: 16876306)
Arch Gen Psychiatry. 1978 Jul;35(7):837-44. (PMID: 678037)
Med Hypotheses. 2015 Apr;84(4):321-6. (PMID: 25649851)
J Clin Psychiatry. 2004 May;65(5):634-51, quiz 730. (PMID: 15163249)
CNS Neurosci Ther. 2011 Dec;17(6):699-704. (PMID: 20961400)
- Accession Number:
0 (DRD3 protein, human)
0 (GABA Agents)
0 (Receptors, Dopamine D3)
614OI1Z5WI (Valproic Acid)
9007-49-2 (DNA)
- Publication Date:
Date Created: 20160617 Date Completed: 20170207 Latest Revision: 20220311
- Publication Date:
20231215
- Accession Number:
PMC4998429
- Accession Number:
10.1097/MD.0000000000003488
- Accession Number:
27310943
No Comments.